Cytosorbents Stock Analysis

CTSO -  USA Stock  

USD 3.42  0.08  2.29%

The latest indifference towards the small price fluctuations of Cytosorbents Cor could raise concerns from institutional investors as the firm it trading at a share price of 3.42 on 214,075 in volume. The company executives did not add any value to Cytosorbents Cor investors in December. However, most investors can still diversify their portfolios with Cytosorbents Cor to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.3. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Cytosorbents Cor partners.
Continue to Trending Equities.

Cytosorbents Stock Analysis 

 
Refresh
The Cytosorbents Cor stock analysis report makes it easy to digest most publicly released information about Cytosorbents Cor and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Cytosorbents Stock analysis module also helps to analyze the Cytosorbents Cor price relationship with some important fundamental indicators such as market cap and management efficiency.

Cytosorbents Stock Analysis Notes

About 47.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.98. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cytosorbents Cor recorded a loss per share of 0.37. The entity had not issued any dividends in recent years. The firm had 1:25 split on the 5th of December 2014. Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey. Cytosorbents Cor operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 195 people. For more info on Cytosorbents Cor please contact Phillip Chan at 732 329 8885 or go to https://www.cytosorbents.com.

Cytosorbents Cor Quarterly Cost of Revenue

2.46 MillionShare

Cytosorbents Cor Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Cytosorbents Cor's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Cytosorbents Cor or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Cytosorbents Cor has very high historical volatility over the last 90 days
Cytosorbents Cor has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 44.34 M. Net Loss for the year was (15.93 M) with profit before overhead, payroll, taxes, and interest of 29.95 M.
Cytosorbents Cor currently holds about 61.04 M in cash with (9.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4.
Cytosorbents Cor has a poor financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Purchase by Phillip Chan of 5462 shares of Cytosorbents Cor

Cytosorbents Cor Upcoming and Recent Events

Earnings reports are used by Cytosorbents Cor to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cytosorbents Cor previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report8th of March 2022
Next Earnings Report3rd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End8th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Cytosorbents Largest EPS Surprises

Earnings surprises can significantly impact Cytosorbents Cor's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2015-11-13
2015-09-30-0.1-0.11-0.0110 
2016-05-09
2016-03-31-0.095-0.080.01515 
2018-03-08
2017-12-31-0.1-0.12-0.0220 
View All Earnings Estimates

Cytosorbents Cor SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Cytosorbents Cor prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Cytosorbents Cor investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Cytosorbents Cor specific information freely available to individual and institutional investors to make a timely investment decision.
7th of January 2022
Unclassified Corporate Event
View
30th of December 2021
Financial Statements and Exhibits. Entry into a Material Definitive Agreement
View
21st of December 2021
Financial Statements and Exhibits. Other Events
View
13th of December 2021
Unclassified Corporate Event
View
4th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
21st of October 2021
Financial Statements and Exhibits. Other Events
View
14th of October 2021
Financial Statements and Exhibits. Other Events
View
13th of October 2021
Financial Statements and Exhibits. Other Events. Results of Operations and Financial Condition
View

Cytosorbents Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Cytosorbents Cor is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cytosorbents Cor backward and forwards among themselves. Cytosorbents Cor's institutional investor refers to the entity that pools money to purchase Cytosorbents Cor's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Seelaus Asset Management LlcCommon Shares23.9 K100 K
Soa Wealth Advisors LlcCommon SharesKK
Blackrock IncCommon Shares2.6 M20.8 M
Vanguard Group IncCommon Shares1.9 M15.2 M
Skylands Capital LlcCommon Shares1.8 M14.9 M
Avenir CorpCommon Shares1.4 M11.3 M
Neuberger Berman Group LlcCommon Shares1.3 M10.2 M
Note, although Cytosorbents Cor's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cytosorbents Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 139.99 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cytosorbents Cor's market, we take the total number of its shares issued and multiply it by Cytosorbents Cor's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Cytosorbents Profitablity

Cytosorbents Cor's profitability indicators refer to fundamental financial ratios that showcase Cytosorbents Cor's ability to generate income relative to its revenue or operating costs. If, let's say, Cytosorbents Cor is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Cytosorbents Cor's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Cytosorbents Cor's profitability requires more research than a typical breakdown of Cytosorbents Cor's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (35.93) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (35.67) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.36.
Last ReportedProjected for 2022
Return on Average Assets(0.13) (0.13) 
Return on Average Equity(0.14) (0.14) 
Return on Invested Capital(0.59) (0.64) 
Return on Sales(0.22) (0.24) 

Management Efficiency

The entity has return on total asset (ROA) of (9.92) % which means that it has lost $9.92 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (21.12) %, meaning that it created substantial loss on money invested by shareholders. Cytosorbents Cor management efficiency ratios could be used to measure how well cytosorbents cor manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Invested Capital is expected to slide to -0.64. The value of Return on Sales is estimated to slide to -0.24. Total Assets is expected to rise to about 111.6 M this year. Current Assets is expected to rise to about 102.3 M this year
Last ReportedProjected for 2022
Book Value per Share 2.35  2.53 
Enterprise Value over EBIT(31.50) (32.33) 
Enterprise Value over EBITDA(34.47) (35.37) 
Price to Book Value 5.00  5.13 
Tangible Assets Book Value per Share 2.66  2.87 
Enterprise Value312.8 M337.5 M
Tangible Asset Value103.4 M111.6 M

Technical Drivers

As of the 21st of January, Cytosorbents Cor shows the Risk Adjusted Performance of 0.0359, mean deviation of 2.84, and Downside Deviation of 3.89. Cytosorbents Cor technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Cytosorbents Cor, which can be compared to its rivals. Please confirm Cytosorbents Cor variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Cytosorbents Cor is priced correctly, providing market reflects its regular price of 3.42 per share. Given that Cytosorbents Cor has jensen alpha of 0.0446, we suggest you to validate Cytosorbents Cor's prevailing market performance to make sure the company can sustain itself at a future point.

Cytosorbents Cor Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Cytosorbents Cor price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average. View also all equity analysis or get more info about triple exponential moving average t3 overlap studies indicator.

Cytosorbents Cor Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cytosorbents Cor insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cytosorbents Cor's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cytosorbents Cor insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Phillip Chan over two weeks ago via Macroaxis 
Purchase by Phillip Chan of 5462 shares of Cytosorbents Cor
Phillip Chan over a month ago via Macroaxis 
Purchase by Phillip Chan of 5000 shares of Cytosorbents Cor
Kathleen Bloch over a month ago via Macroaxis 
Cytosorbents Cor exotic insider transaction detected
Al Kraus over three months ago via Macroaxis 
Exercise or conversion by Al Kraus of 4000 shares of Cytosorbents Cor subject to Rule 16b-3
Deliargyris Efthymios over six months ago via Macroaxis 
Acquisition by Deliargyris Efthymios of 63250 shares of Cytosorbents Cor subject to Rule 16b-3
Kathleen Bloch over a year ago via Macroaxis 
Exercise or conversion by Kathleen Bloch of 7857 shares of Cytosorbents subject to Rule 16b-3
Al Kraus over a year ago via Macroaxis 
Exercise or conversion by Al Kraus of 8000 shares of Cytosorbents subject to Rule 16b-3
Eric Mortensen over a year ago via Macroaxis 
Acquisition by Eric Mortensen of 48700 shares of Cytosorbents subject to Rule 16b-3
Edward Jones over a year ago via Macroaxis 
Exercise or conversion by Edward Jones of 4000 shares of Cytosorbents subject to Rule 16b-3
Phillip Chan over a year ago via Macroaxis 
Exercise or conversion by Phillip Chan of 14100 shares of Cytosorbents subject to Rule 16b-3
Deliargyris Efthymios over a year ago via Macroaxis 
Acquisition by Deliargyris Efthymios of 85500 shares of Cytosorbents subject to Rule 16b-3
Al Kraus over a year ago via Macroaxis 
Exercise or conversion by Al Kraus of 6774 shares of Cytosorbents subject to Rule 16b-3

Cytosorbents Cor Predictive Daily Indicators

Cytosorbents Cor intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cytosorbents Cor stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Cytosorbents Cor Forecast Models

Cytosorbents Cor time-series forecasting models is one of many Cytosorbents Cor's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cytosorbents Cor's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Cytosorbents Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cytosorbents Cor stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cytosorbents shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Cytosorbents Cor. By using and applying Cytosorbents Stock analysis, traders can create a robust methodology for identifying Cytosorbents entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(0.20) (0.22) 
Gross Margin 0.84  0.79 
Profit Margin(0.22) (0.24) 
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Cytosorbents Corporation was founded in 1997 and is based in Monmouth Junction, New Jersey. Cytosorbents Cor operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 195 people.

Current Cytosorbents Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cytosorbents analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cytosorbents analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
12.67Strong Buy6Odds
Cytosorbents Cor current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Cytosorbents analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cytosorbents stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cytosorbents Cor, talking to its executives and customers, or listening to Cytosorbents conference calls.
Cytosorbents Analyst Advice Details

Cytosorbents Stock Analysis Indicators

Cytosorbents Cor stock analysis indicators help investors evaluate how Cytosorbents Cor stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cytosorbents Cor shares will generate the highest return on investment. By understating and applying Cytosorbents Cor stock analysis, traders can identify Cytosorbents Cor position entry and exit signals to maximize returns.
Quick Ratio5.99
Fifty Two Week Low3.1800
Revenue Growth-7.50%
Shares Short Prior Month1.36M
Average Daily Volume Last 10 Day214.89k
Average Daily Volume In Three Month248.06k
Shares Percent Shares Out3.16%
Gross Margins75.55%
Short Percent Of Float3.22%
Forward Price Earnings-10.73
Float Shares40.23M
Fifty Two Week High11.6840
Enterprise Value To Ebitda-7.81
Fifty Day Average4.8332
Two Hundred Day Average7.1940
Enterprise Value To Revenue2.67
Continue to Trending Equities. Note that the Cytosorbents Cor information on this page should be used as a complementary analysis to other Cytosorbents Cor's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Cytosorbents Stock analysis

When running Cytosorbents Cor price analysis, check to measure Cytosorbents Cor's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytosorbents Cor is operating at the current time. Most of Cytosorbents Cor's value examination focuses on studying past and present price action to predict the probability of Cytosorbents Cor's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytosorbents Cor's price. Additionally, you may evaluate how the addition of Cytosorbents Cor to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Is Cytosorbents Cor's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Cor. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Cor listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cytosorbents Cor is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Cor's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Cor's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Cor's market value can be influenced by many factors that don't directly affect Cytosorbents Cor's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytosorbents Cor's value and its price as these two are different measures arrived at by different means. Investors typically determine Cytosorbents Cor value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Cor's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.